Clinical Trial

Brown Fat as Therapeutic Strategy for Obesity and Associated Metabolic Diseases Via Functional Food/Nutraceutical Approach - Molecular Mechanisms of Pentacyclic Triterpenes (BRACE)

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
To examine MA (Maslinic Acid) safety and efficacy in ameliorating insulin resistance and the cardinal features of metabolic syndrome. Chronic exposure to MA as a potent PPARgamma binder nutraceutical over 12 weeks will result in improvement in the features of metabolic syndrome including waist circumference, blood pressure, serum HDL-C level, fasting serum triglycerides and fasting plasma glucose. Expected secondary endpoints include favorable changes in metabolic rate, respiratory quotient, fat oxidation, body composition, weight, BAT/WAT compartments, batokines/adipokines, proinflammatory biomarkers, insulin sensitivity and beta cell function.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-01; most recent amendment 2026-04-05.
Status change: Recruiting → Active, Not Recruiting 2026-04-05
Status change: Not Yet Recruiting → Recruiting 2024-10-10
Trial Details
NCT Number NCT06484543
Lead Sponsor Institute for Human Development and Potential (IHDP), Singapore
Collaborators: National Medical Research Council (NMRC), Singapore
Conditions Diabetes, Brown Adipose Tissue
Enrollment 50 participants
Start Date 2024-08-15
Primary Completion 2027-08-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-09